A blog about chemistry, drug development, science, and technology
This is a follow-up (see previous post here and here) on the proposed acquisition of Plivas by either Actavis or Barr Labs. Now it seems Actavis isn’t going to increase their offer and it looks like Barr Labs may indeed be in a position to acquire Pliva.
• Actavis, outbid on Pliva, weighs new M&A dealsMovers: Way cleared for Barr to buy drug maker
• Pliva - Marketplace by Bloomberg - International Herald Tribune
• Actavis Won’t Raise Pliva Bid, Clearing Way for Barr
• Barr biogenerics: big payoff, big risk - Sep. 15, 2006
I really think that, barring some regulatory hurdle that isn’t apparent now, Barr will end up with Pliva probably before the end of the year. However, it may well be the Barr is paying more that Pliva is trulyy worth. Only time will tell.
Technorati Tags: Actavis, Barr Labs, pharma M&A, pharmaceutical deals, Pliva
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 0.876 seconds